Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) gapped down prior to trading on Friday . The stock had previously closed at $5.55, but opened at $6.13. Catalyst Pharmaceuticals shares last traded at $6.04, with a volume of 291,206 shares trading hands.
A number of equities analysts have commented on the company. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research note on Wednesday, July 31st. Cantor Fitzgerald lifted their target price on Catalyst Pharmaceuticals from $10.00 to $12.00 in a research note on Thursday, August 8th. BidaskClub upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. Finally, SunTrust Banks restated a “buy” rating and issued a $11.00 target price (up from $9.00) on shares of Catalyst Pharmaceuticals in a research note on Thursday, August 8th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $8.54.
The stock has a fifty day moving average price of $5.68 and a two-hundred day moving average price of $4.49. The company has a market cap of $712.27 million, a P/E ratio of -18.82 and a beta of 2.38. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.09 and a quick ratio of 5.07.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.07. The business had revenue of $28.84 million for the quarter, compared to the consensus estimate of $17.99 million. The business’s quarterly revenue was up 2883900.0% on a year-over-year basis. During the same period last year, the firm posted ($0.06) EPS. As a group, analysts forecast that Catalyst Pharmaceuticals Inc will post 0.34 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 678.1% during the second quarter. Meeder Asset Management Inc. now owns 13,251 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 11,548 shares during the last quarter. Bank of Montreal Can raised its holdings in shares of Catalyst Pharmaceuticals by 159.1% during the second quarter. Bank of Montreal Can now owns 12,953 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 7,953 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at approximately $55,000. Paradigm Capital Management Inc. NY bought a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at approximately $77,000. Finally, Jefferies Group LLC bought a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at approximately $77,000. 59.81% of the stock is currently owned by institutional investors.
About Catalyst Pharmaceuticals (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Featured Story: Limitations to arbitrage trading
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.